Research Topics
| S B HagaSummaryAffiliation: Duke University Medical Center Country: USA Publications
Research Grants
|
Detail Information
Publications
Public knowledge of and attitudes toward genetics and genetic testingSusanne B Haga
Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
Genet Test Mol Biomarkers 17:327-35. 2013..Variable health literacy and genetic knowledge may pose significant challenges to engaging the general public in personal genomics, specifically with respect to promoting risk comprehension and healthy behaviors...
Primary care physicians' knowledge of and experience with pharmacogenetic testingS B Haga
Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
Clin Genet 82:388-94. 2012..Development of effective tools for guiding PCPs in the use of PGx tests should be a high priority...- Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testingS S Haga
Institute for Genome Sciences and Policy, Duke University, 304 Research Drive, Durham, NC 27708, USA
Clin Genet 82:115-20. 2012..At this early stage of PGx testing, the role of geneticists and genetic counselors is unclear. However, their experience may aid in readying PGx testing and informing delivery strategies into clinical practice... - Effect of genetic testing for risk of type 2 diabetes mellitus on health behaviors and outcomes: study rationale, development and designAlex H Cho
Center for Personalized Medicine, Duke University, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
BMC Health Serv Res 12:16. 2012.... - Survey of US public attitudes toward pharmacogenetic testingS B Haga
Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
Pharmacogenomics J 12:197-204. 2012..Given differences in interest among some groups, providers should clearly discuss the purpose of testing, alternative testing options (if available) and policies to protect patient privacy and confidentiality... - Public perspectives about pharmacogenetic testing and managing ancillary findingsSusanne B Haga
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
Genet Test Mol Biomarkers 16:193-7. 2012..To assess public attitudes toward PGx testing, ancillary disease risk information and related clinical issues, we conducted a series of focus groups... - Professional perspectives about pharmacogenetic testing and managing ancillary findingsSusanne B Haga
Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
Genet Test Mol Biomarkers 16:21-4. 2012..Additional educational resources, access to genetic specialists, and clear clinical guidelines about the use of PGx testing would greatly facilitate appropriate use of testing... - Ethical issues of predictive genetic testing for diabetesSusanne B Haga
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
J Diabetes Sci Technol 3:781-8. 2009.... - Analysis of educational materials and destruction/opt-out initiatives for storage and use of residual newborn screening samplesSusanne B Haga
Institute for Genome Sciences and Policy, Sanford School of Public Policy, Duke University, Durham, North Carolina 27708, USA
Genet Test Mol Biomarkers 14:587-92. 2010..Development of new policies regarding storage and use of residual NBS samples will require careful consideration of impact on NBS programs, parent and provider educational materials, and respect for parents among other issues... - Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profilingSusanne B Haga
Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
J Gen Intern Med 26:834-40. 2011..There is considerable controversy as to how, and even whether, to incorporate these tests into routine medical care... - Public perspectives regarding data-sharing practices in genomics researchS B Haga
Institute for Genome Sciences and Policy and Sanford School of Public Policy, Duke University, Durham, NC 27708, USA
Public Health Genomics 14:319-24. 2011..Re-identification of research participants from sequence data has been shown possible, raising concerns of participants' privacy... - Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditionsSusanne B Haga
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
Genet Med 13:723-8. 2011..quot; We aimed to assess public interest and concerns about pharmacogenetic tests and ancillary information... - Consideration of patient preferences and challenges in storage and access of pharmacogenetic test resultsSusanne B Haga
Institute for Genome Sciences and Policy and Sanford School of Public Policy, Duke University, Durham, NC 27708, USA
Genet Med 13:887-90. 2011..We aimed to assess public interest and concerns regarding sharing and storage of pharmacogenetic test results that would facilitate the reuse of pharmacogenetic data across a lifetime of care... - Ensuring the safe use of genomic medicine in childrenSusanne B Haga
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
Clin Pediatr (Phila) 48:703-8. 2009..In particular, the importance of counseling, context, consent, communication, and follow-up in the delivery of genomic risk testing to children and adolescents is highlighted... 
Adding pharmacogenetics information to drug labels: lessons learnedSusanne B Haga
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
Pharmacogenet Genomics 16:847-54. 2006..We review the reasons behind the cautious label changes and discuss some of the lessons that can be learned from these experiences...- Defining the spectrum of genome policySusanne B Haga
Institute for Genome Sciences and Policy, Duke University, 101 Science Drive, Box 3382, Durham, North Carolina 27708, USA
Nat Rev Genet 7:966-72. 2006..Here we discuss the spectrum of current issues and debates in genome policy, and how to actively engage all affected stakeholders to promote effective policy making... - Prescribing BiDil: is it black and white?Susanne B Haga
Center for Genomic Medicine, Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
J Am Coll Cardiol 48:12-4. 2006..Until more accurate selection criteria are developed to identify patients who are most likely to benefit, both clinicians and the general public will need to consider the unique issues raised by BiDil... - Pharmacogenetic testing: not as simple as it seemsSusanne B Haga
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina27708, USA
Genet Med 10:391-5. 2008..These issues have implications for informed consent and genetic counseling requirements, and for the role of health professionals... - The potential of a placebo/nocebo effect in pharmacogeneticsS B Haga
Duke University, Institute for Genome Sciences and Policy, Durham, NC 27708, USA
Public Health Genomics 12:158-62. 2009..Studies are needed to investigate the impact of pharmacogenetic information of therapeutic outcome... - Teaching resources for geneticsSusanne B Haga
Institute for Genome Sciences and Policy, Duke University, 101 Science Drive, Durham, North Carolina 27708, USA
Nat Rev Genet 7:223-9. 2006..It also describes an integrated approach to teaching genetics, emphasizes the need for continuing teacher education, and encourages the involvement of geneticists and health professionals in providing a teaching resource... - Public perspectives on returning genetics and genomics research resultsJ O'DANIEL
Institute for Genome Sciences and Policy and Sanford School of Public Policy, Duke University, Durham, NC 27708, USA
Public Health Genomics 14:346-55. 2011..Public attitudes, particularly those of African-Americans, toward this issue have been understudied... - Practical ethics: establishing a pathway to benefit for complex pharmacogenomic testsS B Haga
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
Clin Pharmacol Ther 90:25-7. 2011..However, the level of evidence required to establish clinical utility is often the subject of debate. Determining the most efficient and effective pathway to benefit for a given test is therefore both a practical and an ethical concern... - Considerations for the impact of personal genome information: a study of genomic profiling among genetics and genomics professionalsJulianne M O'Daniel
Duke Institute for Genome Sciences and Policy, Duke University, 450 Research Drive, LSRC B342C, Box 91009, Durham, NC 27708, USA
J Genet Couns 19:387-401. 2010.... - Translating genomic biomarkers into clinically useful diagnosticsGeoffrey S Ginsburg
Center for Genomic Medicine, Institute for Genome Sciences and Policy, Duke University, Box 3382, Durham, NC 27708, USA
Expert Rev Mol Diagn 6:179-91. 2006..In addition, efforts will be needed to educate health professionals and the public about genomics-based tools, revise regulatory oversight mechanisms, and ensure privacy safeguards of the information generated from these new tests... - Factors influencing uptake of pharmacogenetic testing in a diverse patient populationJ O'DANIEL
Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
Public Health Genomics 13:48-54. 2010..In this study, we aimed to identify the major reasons why patients would or would not consider PGx testing and whether these factors differed by race, socioeconomic and insurance status, and medical history... - Ethical, legal, and social implications of biobanks for genetics researchSusanne B Haga
Institute for Genome Sciences and Policy, Center for Genome Ethics, Law, and Policy, Duke University, Durham, NC 27708, USA
Adv Genet 60:505-44. 2008..K., Sweden, and Estonia, and the proposal for a U.S. population cohort study. The dependence on public participation requires clear and transparent policies developed through inclusive processes... - Impact of limited population diversity of genome-wide association studiesSusanne B Haga
From the Institute for Genome Sciences and Policy and Sanford School of Public Policy, Duke University, Durham, North Carolina
Genet Med 12:81-4. 2010.... - Using pharmacogenetics to improve drug safety and efficacySusanne B Haga
The Center for the Advancement of Genomics, Rockville, MD, USA
JAMA 291:2869-71. 2004 - Genetics. FDA races in wrong directionSusanne B Haga
Center for the Advancement of Genomics, Rockville, MD 20850, USA
Science 301:466. 2003..We also encourage that increased funding be committed to this important issue... - Letting the genome out of the bottleSusanne B Haga
N Engl J Med 358:2184; author reply 2185. 2008 - Genomic profiling to promote a healthy lifestyle: not ready for prime timeSusanne B Haga
Center for the Advancement of Genomics, 1901 Research Blvd, Sixth Floor, Rockville, Maryland 20850, USA
Nat Genet 34:347-50. 2003 - The genetics workforce and workloadSusanne B Haga
Genet Med 5:55-7. 2003
Research Grants
- Exploring Attitudes About Data Disclosure and Data-Sharing in Genomics ResearchSusanne Haga; Fiscal Year: 2007..The success of large-scale genomics research initiatives will depend on the support and participation of the public and therefore, their views are critically important to obtain. ..
- Pharmacogenetic Testing: Challenges of Clinical IntegrationSusanne Haga; Fiscal Year: 2009..This study will also help inform determinations of whether new health infrastructures for pharmacogenetics are required beyond current systems for successful population-wide integration. ..
- Pharmacogenetic Testing: Challenges of Clinical IntegrationSusanne B Haga; Fiscal Year: 2010..This study will also help inform determinations of whether new health infrastructures for pharmacogenetics are required beyond current systems for successful population-wide integration. ..